About the role
The Mission
Drug discovery has a translation problem: more than 95% of drugs that succeed in animal models fail in humans. We're building the alternative: human-first drug discovery, powered by organoids and AI, running on real human biology from the very first experiment.
Our platform is 87% concordant with clinical patient data - a vast improvement over the 3% translational success rate of animals. We’ve demonstrated the ability to model immunotoxicology, immunogen stimulation, and two autoimmune diseases with more on the way. Numerous pharma partners including 3 Fortune 500 companies are already using the platform. We've raised ~$30M from AIX Ventures, Marc Benioff, Jeff Dean, and Y Combinator. With the FDA Modernization Act 3.0 and the FDA's March 2026 validation framework, the regulatory tailwinds only continue to get stronger.
The opportunity ahead of the company is generational: build the first scaled engine for generating real human biological data, and use it to fundamentally change how medicines are discovered.
What you'll do
-
Design, prototype, and build fully autonomous workcells across the entire organoid lifecycle — seeding, culture maintenance, perturbation, harvest, and assay execution. You should have deep, credible experience in designing and deploying similar systems.
-
Own all mechanical engineering, robotics, and computer vision required to move the platform from discretely automated to fully end-to-end. You should have the academic credentials and work experience to think through and own the entire development roadmap of these workcells.
